Results 141 to 150 of about 74,377 (332)

N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R) [PDF]

, 2023
Giovanni Graziano, Pietro Delre, Francesca Carofiglio, José Brea, Alessia Ligresti, Magdalena Kostrzewa, Chiara Riganti, Claudia Gioé-Gallo, María Majellaro, Orazio Nicolotti, Nicola Antonio Colabufo, Carmen Abate, Marı́a Isabel Loza, Eddy Sotelo, Giuseppe Felice Mangiatordi, Marialessandra Contino, Angela Stefanachi, Francesco Leonetti   +17 more
openalex   +1 more source

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective/Background This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long‐term, open‐label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug–device combination of 5.2 mg dihydroergotamine in a single‐use nasal delivery device for the ...
Jessica Ailani, Larry Charleston IV, Shannon Strom, Detlef Albrecht, Robert Cowan   +4 more
wiley   +1 more source

Tumor necrosis factor α, agonist and antagonists of cannabinoid receptor type 1 and type 2 alter the immunephenotype of stem cells from human exfoliated deciduous teeth [PDF]

, 2022
Marizia Trevizani, Laís Lopardi Leal, João Vitor Paes Rettore, Gilson Costa Macedo, Caio César de Souza Alves, Sandra Bertelli Ribeiro de Castro, Antônio Márcio Resende Carmo, Silvioney Augusto Silva, Carlos Magno Costa Maranduba, Fernando Sá Silva   +9 more
openalex   +1 more source

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the efficacy of cannabis for the treatment of acute migraine. Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.
Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton   +6 more
wiley   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Annual Research Review: Neural mechanisms of eating disorders in youth – from current theory and findings to future directions

Journal of Child Psychology and Psychiatry, EarlyView.
Eating disorders are prevalent and profoundly debilitating psychiatric conditions with multifactorial etiology that frequently manifest during adolescence. This developmental stage is characterized by significant neurostructural and neurofunctional change, which may create a context conducive to the emergence of eating pathology.
Kelsey Hagan, E. Caitlin Lloyd, Sasha Gorrell   +2 more
wiley   +1 more source

The synthetic cannabinoids menace: a review of health risks and toxicity

European Journal of Medical Research
Synthetic cannabinoids (SCs) are chemically classified as psychoactive substances that target the endocannabinoid system in many body organs. SCs can initiate pathophysiological changes in many tissues which can be severe enough to damage the normal ...
Ayman Alzu’bi, Fatimah Almahasneh, Ramada Khasawneh, Ejlal Abu-El-Rub, Worood Bani Baker, Raed M. Al-Zoubi   +5 more
doaj   +1 more source

Full‐Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open‐Label Study

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The aim of this Phase I/II open‐label study was to assess the safety and efficacy of NTI164, a novel full‐spectrum medicinal cannabis plant extract 0.08% Δ‐9‐tetrahydrocannabinol (THC), in Rett syndrome (RTT). Methods Eleven female participants (5–16 years) with a pathogenic variant in the MECP2 gene were recruited to this study, receiving
B. A. Keating, Y. Ogru, T. G. Duthy, L. Douglas, K. Lichkus, E. Isikgel, M. C. Fahey, C. Ellaway   +7 more
wiley   +1 more source

Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and ‘cannabinoid‐like’ receptors in small arteries [PDF]

, 2010
C. Stevens Marc Daly, RA Ross, Jennifer Whyte, Christopher M. Henstridge, AJ Irving, J.C. McGrath   +5 more
openalex   +1 more source

Current Trends, Future Prospects and Constraints of Whole Microalgae and Their Fractions as a Functional Feed Ingredient for Animals

Journal of Animal Physiology and Animal Nutrition, EarlyView.
ABSTRACT Microalgae are a highly diverse group of unicellular organisms that grow in a wide range of aquatic environments and are widely used as dietary supplements for both human and animal applications. Microalgae are rich in lipids, proteins, carbohydrates and other valuable bioactive components such as pigments, antioxidants and vitamins.
Sietse Jan Koopmans, Simon Roques, Edoardo Zaccaria, Annemarie Mens, Soumya Kanti Kar   +4 more
wiley   +1 more source